Nieuwenhuyzen-de Boer, G. M.
Hofhuis, W.
Reesink-Peters, N.
Willemsen, S.
Boere, I. A.
Schoots, I. G.
Piek, J. M. J.
Hofman, L. N.
Beltman, J. J.
van Driel, W. J.
Werner, H. M. J.
Baalbergen, A.
van Haaften-de Jong, A. M. L. D.
Dorman, M.
Haans, L.
Nedelcu, I.
Ewing-Graham, P. C.
van Beekhuizen, H. J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Funding for this research was provided by:
ZonMw (843001805)
Article History
Received: 23 November 2021
Accepted: 27 March 2022
First Online: 13 May 2022
Change Date: 11 June 2022
Change Type: Update
Change Details: G. M. Nieuwenhuyzen-de Boer's name was corrected.
Disclosure
: I.A.B. reports translational research (ctDNA) to the employer (Erasmus MC Cancer Institute) grant by GSK. The study was funded by the Netherlands Organization for Health Research and Development (ZonMw), number 843001805. No relevant conflicts of interest.
: The study is carried out according to the standards outlined in the Declaration of Helsinki. Patients from the following Dutch hospitals were included: Albert Schweitzer (Dordrecht), Bravis (Bergen op Zoom), Catharina Cancer Institute (Eindhoven), Erasmus MC (Rotterdam), Franciscus Gasthuis and Vlietland (Rotterdam), Groene Hart Hospital (Gouda), Haags Medisch Centrum (The Hague), Haga Hospital (The Hague), Leiden University Medical Center (Leiden), Maastricht UMC+ (Maastricht), Medisch Spectrum Twente (Enschede), Netherlands Cancer Institute (Amsterdam), and Reinier de Graaf Groep (Delft). Patients received verbal and written information from their gynecologists during the intake for surgery. Informed consent to use the data for analyses was obtained from all participants. Randomization took place after a patient had signed the informed consent form. All data are pseudonymized. Participants could withdraw from the study at any time without providing a reason.